Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.

British journal of haematology - 1 May 2024

Ferrer-Marín Francisca, Hernández-Boluda Juan Carlos, Alvarez-Larrán Alberto

Abstract excerpt

Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by an increased risk of vascular complications and a tendency to progress to myelofibrosis and acute leukaemia. ET patients have traditionally been stratified into two thrombosis risk categories based on age older than 60 years and a history of thrombosis. More recently, the revised IPSET-thrombosis scoring system, which accounts for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Platelet Aggregation Inhibitors

Share to Receptors, Thrombopoietin

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 38586911
DOI: 10.1111/bjh.19403

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.PMID 38586911Read ↗

Essential thrombocythemia treatment algorithm 2018.Semantic proximity Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.Semantic proximity Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

One thousand patients with essential thrombocythemia: the Mayo Clinic experience.Semantic proximity Read ↗

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

Essential thrombocythemia.Semantic proximity Read ↗

Austrian recommendations for the management of essential thrombocythemia.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

New advances in the pathogenesis and therapy of essential thrombocythemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.